Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss

• Published in: Bone (New York, N.Y.) Vol. 97; pp. 222 - 232
• Main Authors: Zhang, Yan, Li, Xiao-Li, Sha, Nan-Nan, Shu, Bing, Zhao, Yong-Jian, Wang, Xin-Luan, Xiao, Hui-Hui, Shi, Qi, Wong, Man-Sau, Wang, Yong-Jun
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2017
• Subjects: Angiotensin II - metabolism; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Animals; Biomarkers - blood; Biomarkers - urine; Bone; Bone and Bones - diagnostic imaging; Bone and Bones - drug effects; Bone and Bones - pathology; Bone Resorption - blood; Bone Resorption - complications; Bone Resorption - pathology; Bone Resorption - urine; Calcium - metabolism; Captopril; Captopril - adverse effects; Diabetes; Diabetes Mellitus, Experimental - blood; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Experimental - urine; Femur - diagnostic imaging; Femur - drug effects; Femur - pathology; Fibrosis; Kidney; Kidney - diagnostic imaging; Kidney - drug effects; Kidney - pathology; Mice, Inbred C57BL; Orthopedics; Osteoblasts - drug effects; Osteoblasts - metabolism; Osteoclasts - drug effects; Osteoclasts - metabolism; Osteoporosis; Renin-angiotensin system; Renin-Angiotensin System - genetics; RNA, Messenger - genetics; RNA, Messenger - metabolism; Tibia - diagnostic imaging; Tibia - drug effects; Tibia - pathology; Vitamin D3 24-Hydroxylase - metabolism; X-Ray Microtomography; Osteoporosis; Diabetes; Bone; Renin-angiotensin system; Captopril; Kidney
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2017.01.029

Abstract The components of renin-angiotensin system (RAS) are expressed in the kidney and bone. Kidney disease and bone injury are common complications associated with diabetes. This study aimed to investigate the effects of an angiotensin-converting enzyme inhibitor, captopril, on the kidney and bone of db/db mice. The db/db mice were orally administered by gavage with captopril for 8 weeks with db/+ mice as the non-diabetic control. Serum and urine biochemistries were determined by standard colorimetric methods or ELISA. Histological measurements were performed on the kidney by periodic acid-schiff staining and on the tibial proximal metaphysis by safranin O and masson-trichrome staining. Trabecular bone mass and bone quality were analyzed by microcomputed tomography. Quantitative polymerase chain reaction and immunoblotting were applied for molecular analysis on mRNA and protein expression. Captopril significantly improved albuminuria and glomerulosclerosis in db/db mice, and these effects might be attributed to the down-regulation of angiotensin II expression and the expression of its down-stream profibrotic factors in the kidney, like connective tissue growth factor and vascular endothelial growth factor. Urinary excretion of calcium and phosphorus markedly increased in db/db mice in response to captopril. Treatment with captopril induced a decrease in bone mineral density and deterioration of trabecular bone at proximal metaphysis of tibia in db/db mice, as shown in the histological and reconstructed 3-dimensional images. Even though captopril effectively reversed the diabetes-induced changes in calcium-binding protein 28-k and vitamin D receptor expression in the kidney as well as the expression of RAS components and bradykinin receptor-2 in bone tissue, treatment with captopril increased the osteoclast-covered bone surface, reduced the osteoblast-covered bone surface, down-regulated the expression of type 1 collagen and transcription factor runt-related transcription factor 2 (markers for osteoblastic functions), and up-regulated the expression of carbonic anhydrase II (marker for bone resorption). Captopril exerted therapeutic effects on renal injuries associated with type 2 diabetes but worsened the deteriorations of trabecular bone in db/db mice; the latter of which was at least in part due to the stimulation of osteoclastogenesis and the suppression of osteogenesis by captopril.